ArticleFrontiers in artificial intelligence2026
ProtT5-MSCRNet: a multi-scale convolutional and channel-recalibrated deep learning framework for anticancer peptide prediction.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyclic Peptides as Modulators of Protein-Protein Interactions: A Survival Guide from Discovery Platforms to AI-Driven Design.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer is a leading cause of mortality worldwide. Anticancer peptides (ACPs) are promising therapeutic candidates due to their low toxicity, favorable biocompatibility, and selective anticancer activity; however, experimental ACP identification and screening remain labor-intensive, time-consuming, and costly. Methods: We developed ProtT5-MSCRNet, an end-to-end deep learning framework for ACP prediction that integrates ProtT5-based evolutionary representations, multi-scale convolutional feature extraction, channel-wise attention recalibration, and robust optimization strategies. Results: Experiments on two independent benchmark datasets showed that ProtT5-MSCRNet outperformed state-of-the-art ACP prediction methods. The model achieved ACC/SN/SP/MCC values of 0.954/0.874/0.983/0.881 on Test Set 1 and 0.984/0.980/0.987/0.967 on Test Set 2. Ablation studies and visualization analyses further supported the effectiveness and interpretability of the proposed model. Discussion: ProtT5-MSCRNet provides a robust, accurate, and biologically meaningful computational tool for facilitating ACP identification and accelerating anticancer peptide discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.